Standardized Annual Returns (thru February 28)
  
    | Year-to-date | 
    1 year | 
    5 years | 
    10 years | 
    Since Incep. | 
  
  
    | 0.3% | 
    10.8% | 
    -- | 
    -- | 
    17.1% | 
  
 
       
          Market Correlations
          
            | versus... | 
            Beta | 
            R-squared | 
          
          
            | S&P500  | 
            1.33 | 
            58% | 
          
          
            | MSCI EAFE | 
            0.87 | 
            35% | 
          
          
            | MSCI Emg. Mkts. | 
            0.68 | 
            11% | 
          
        
	
   
      
      Technical Indicators
      
        | Recent close | 
        $34.56 | 
      
      
        | 30d moving avg. | 
        $35.66 | 
      
      
        | Annualized volatility | 
        18.6% | 
      
      
        | Short interest (ETF) | 
        0.0% | 
      
      
        | Relative strength (RSI) | 
        44 | 
      
      
   
      
      Liquidity measures
      
        | Avg. volume (thou.) | 
        3 | 
        
      
        | Turnover | 
        0.8% | 
      
      
        | Bid/Ask (% of price) | 
        0.30% | 
      
      
        | ADV underlying (mns) | 
        $1,655 | 
      
      
      
 
    
 
    
   
  
			
				  | 	
				There were no matches found with other funds under coverage. | 
			
			
  
  
      Content on this tab for subscribers only**
      
      
        
          
            |   | 
            2020 | 
            2021 | 
            2022 | 
            2023 | 
            2024 | 
            2025E | 
            2026E | 
          
          
            | Sales per share | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
          
          
            | Earnings per share | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
          
          
            Dividends per share   | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
          
          
            | Book value per share | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
            ** | 
          
        
   
    
        
          
            | Sales per share growth | 
              | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
          
          
            | EPS growth | 
              | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
          
          
       
        
          
            | Sales per share growth | 
              | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
          
          
            | EPS growth | 
              | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
            **% | 
          
          
         
      
      
      
  
    
      | Long term EPS growth est. | 
       **% | 
        | 
      Debt-to-equity | 
       **x | 
      
    
      | Asset turnover | 
       **% | 
        | 
      Assets-to-equity | 
       **x | 
      
  
   
  
   
  
    
  
	
    Revision activity*
    	
      	  | 
    	
     	
         | *Six months ago = 100 | 
        
	
	
   
  
    
	
	
    Compound annual growth rates
        
           | 
        
	
	
        
    
  
      Content on this tab for subscribers only
	
    
      
        |   | 
        2024 | 
        2025E | 
        2026E | 
        
      
        | Price-to-sales | 
        ** | 
        ** | 
        ** | 
        
      
        | Price-to-earnings | 
        ** | 
        ** | 
        ** | 
        
      
        | Price-to-cash flow | 
        ** | 
        ** | 
        ** | 
        
      
        | Price-to-growth  | 
        ** | 
        ** | 
        ** | 
        
      
        | Price-to-book value | 
        ** | 
        ** | 
        ** | 
        
      
        | Yield | 
        ** | 
        ** | 
        ** | 
        
      
 
     
      
		   
     
    
      	
      		SPECULATIVE | 
		
        
        	| Deeply undervalued but risky. A rating of SPECULATIVE is assigned to ETFs with ALTAR Scores in the top quintile (the top 20%) of their category, indicating exceptional appreciation potential. However, often these are narrowly-focused funds or in industries with structural issues, which may also make them very risky. Nonetheless they may still be useful as part of a well-diversified portfolio. | 
      
     
	
    	
	
		
  
            
            | Calculation of ALTAR Score™ | 
            
              | Avg. Return on Equity | 
              13.5 | 
              % | 
               
            
              | Divided by: Fwd. P/BV | 
              1.3 | 
              x | 
               
            
              | Less: Expense ratio | 
              135 | 
              bp | 
               
            
              | Equals: ALTAR Score | 
              9.3 | 
              % | 
               
            
               |  
            
                More information on ALTAR Score™ |  
             
    
	     
	 | 
     | 
    
      
    | 
  
  
	
    
    	
			
				
   				
      				COMPOSITE RATING | 
      				1.59 | 
      				CATEGORY AVERAGE | 
     					1.58 | 
   				 
   				
   					|   | 
   				 
   				
						The composite rating is a weighted average of analysts' 
						consensus recommendations for individual ETF constituents, based on the following scale:  
						 
						BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.
						 
						 
						Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be
						more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation. 
						 |    				
   				 
				     			
			 | 
			  | 
			 |